‘We’re losing to cottage cheese’: The protein-maxxing craze is hurting cream cheese sales
U.S. cottage cheese sales have more than doubled from levels seen in 2021. Source：MarketWatch
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won’t compound GLP1 medications like Zepbound in the future. Source：MarketWatch
Layoffs with dignity? Why these tech companies are offering free laptops and LinkedIn Premium.
Some tech companies are giving more generous severance packages, but here’s what to keep in mind. Source：MarketWatch
Nvidia, AMD and other chip stocks rebound. Is the ‘violent’ AI selloff over?
Analysts warn of further volatility ahead, though there are two new factors that work in the AI trade’s favor. Source：MarketWatch
These three stars need to align before investors rush back into stocks, Bank of America strategist says
Despite the steep drop in equity markets this week, investors should wait for several developments in other asset markets before rushing back into stocks,…
The crypto industry has found new ways to grow. Making money from them is another story
Coinbase, Robinhood and Circle are expanding into stablecoins, payments and prediction markets, but their latest earnings show how hard it is to escape…
The S&P 500 has become a big AI bet. Here are some simple alternatives.
The largecap index is nowhere near as diversified as you think. Source：MarketWatch
U.S. added 165,000 jobs in October, blowing past 65,000 estimate
The unemployment rate unexpectedly fell to 4.1%. The strong showing surely puts a December rate hike in play, but next week's inflation numbers and the fate of…
Why Democrats should use their new power to embrace Trump’s tariffs
Blaming tariffs on manufactured goods for the soaring price of gasoline is the wrong solution to the affordability crisis. Source：MarketWatch
The wealthiest 10% of Americans are pulling ahead of everyone else. This is what’s making them richer.
The wealthiest 10% have a median net worth that is $800,000 greater than it was three years ago. Source：MarketWatch
Moderna’s stock jumps after biotech raises sales outlook
The company lifted its revenue outlook for the year, saying it expects revenue to grow as much as 25% in 2026. Source：MarketWatch
Goldman’s new gold target: Why the Wall Street bank is saying it’s early to buy the yellow metal
Strategists at the investment bank said the change in expectations is down to the Federal Reserve’s hawkish shift. Source：MarketWatch